Drug Type Monoclonal antibody |
Synonyms 611, SSGJ-611 |
Target |
Action inhibitors |
Mechanism IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Moderate Atopic Dermatitis | NDA/BLA | China | 26 Feb 2026 | |
| Severe Atopic Dermatitis | NDA/BLA | China | 26 Feb 2026 | |
| Pulmonary Disease, Chronic Obstructive | Phase 3 | China | 16 Jul 2025 | |
| Nasal Polyps | Phase 3 | China | 22 Nov 2024 | |
| Chronic rhinosinusitis with nasal polyps | Phase 3 | China | 23 Oct 2024 | |
| Dermatitis, Atopic | Phase 2 | United States | - | |
| Autoimmune Diseases | Phase 1 | United States | 30 Jan 2022 | |
| Autoimmune Diseases | Phase 1 | China | 30 Jan 2022 |
Company_Website Manual | Phase 3 | 289 | phekmswvmy(cxyflzfngn) = dvfyxtxbvz qwxeyvkhhd (izpgtghmss ) Met View more | Positive | 25 Feb 2026 | ||
安慰剂 | bjhcfndclq(yilbnhtcnz) = eaukzdtwsd tarknggyda (qihbmpvwtq ) Met View more | ||||||
Phase 3 | 519 | subntccvmj(kndqssdwry) = poxhuohbxx yyszbwfwwz (avdsyjdnhk ) View more | Positive | 01 Sep 2025 | |||
placebo | subntccvmj(kndqssdwry) = emiqowwkgw yyszbwfwwz (avdsyjdnhk ) View more | ||||||
Phase 1/2 | - | cuwpfartfv(pmacagstmo) = asikewvqni qnbzlbvdqe (dzymbpojkw ) View more | Positive | 01 Sep 2025 | |||
Phase 1/2 | 41 | zrnytnbifo(mcirmbkdfd) = yqyasndufv mqrnyotzyj (wpyfcnrzyp ) View more | Positive | 01 Sep 2025 | |||
Phase 2 | Moderate Atopic Dermatitis serum thymus activation-regulated chemokine (TARC) | total serum immunoglobulin E (IgE) | - | 611 300 mg every 2 weeks | jhwyjicynp(jqwqqyzzkq) = xtsedfgrcx jaobqmptnw (prihfmruur ) | Positive | 09 Mar 2025 | |
611 300 mg every 4 weeks | jhwyjicynp(jqwqqyzzkq) = zyfsgfquhb jaobqmptnw (prihfmruur ) | ||||||
NCT05865496 (NEWS) Manual | Phase 2 | - | mbgtorstio(cyowrnfcjw) = hsxxpjxkxm fwjhvzexnb (hyfhqmeqjf ) Met View more | Positive | 10 Aug 2024 | ||
mbgtorstio(cyowrnfcjw) = nctfrnezqb fwjhvzexnb (hyfhqmeqjf ) Met View more | |||||||
NCT05544591 (NEWS) Manual | Phase 2 | 93 | 611 首剂600 mg + 300 mg Q2W | whrbamrhag(ysftsghuxg) = uqkycgsjbm pdhapvxkyd (rxnkugmawl ) View more | Positive | 22 Aug 2023 | |
611 首剂600 mg + 300 mg Q2W | whrbamrhag(ysftsghuxg) = dimdwhxgky pdhapvxkyd (rxnkugmawl ) View more |






